Abingworth Attracts $375M For Its New Bioventures Fund
This article was originally published in Start Up
The committed capital is nearly half what the 40-year-old firm raised from its previous vehicle and its sidecar in 2007–2008, but it's a huge sum compared with what most life science VCs can drum up these days.
You may also be interested in...
The biotech took advantage of rising investor interest in RNAi to pull off a heavily oversubscribed IPO.
The profit-oriented evergreen fund of Britain’s charitable foundation The Wellcome Trust, Syncona, has invested £12 million in an academic spin-out to develop and commercialize therapies for treating degenerative eye diseases.
The Norwegian biotech is keen to show it is not a one-trick pony, but its future might lie in the embrace of its big pharma partner Bayer.